ATI RN
ATI Proctored Pharmacology Test
1. Before administering lithium to a client with bipolar disorder who has been taking the medication for 1 year, the nurse should check to see that which of the following tests has been completed?
- A. Thyroid hormone assay
- B. Liver function tests
- C. Erythrocyte sedimentation rate
- D. Brain natriuretic peptide
Correct answer: A
Rationale: The correct answer is to check the thyroid hormone assay. Long-term lithium use can result in thyroid dysfunction, making it crucial to monitor the client's thyroid function regularly to detect any abnormalities early and prevent potential complications. Liver function tests (choice B) are not specifically associated with lithium therapy. Erythrocyte sedimentation rate (choice C) is a nonspecific test for inflammation and not directly related to lithium therapy. Brain natriuretic peptide (choice D) is a test used to diagnose heart failure and is not relevant to monitoring lithium therapy.
2. A client has a new prescription for Lisinopril. Which of the following instructions should the nurse include?
- A. Avoid salt substitutes.
- B. Take this medication at bedtime.
- C. Increase your intake of potassium-rich foods.
- D. Take this medication with food.
Correct answer: A
Rationale: The correct instruction for a client prescribed Lisinopril is to avoid salt substitutes. Lisinopril, an ACE inhibitor, can lead to hyperkalemia, hence the importance of avoiding salt substitutes that may contain potassium. Instructing the client to avoid salt substitutes helps prevent potential adverse effects of increased potassium levels.
3. When teaching a client with a new prescription for Sulfasalazine, which instruction should the nurse include?
- A. Expect orange discoloration of urine and skin.
- B. Increase your intake of high-sodium foods.
- C. Take the medication with a full glass of milk.
- D. Expect your stools to be black and tarry.
Correct answer: A
Rationale: The correct instruction to include when teaching a client with a new prescription for Sulfasalazine is to expect orange discoloration of urine and skin. Sulfasalazine can cause this harmless side effect, which does not necessitate discontinuation of the medication. It is crucial for the nurse to educate the client about this expected outcome to prevent unnecessary concern or discontinuation of the medication. Choices B, C, and D are incorrect. Increasing intake of high-sodium foods is not recommended with Sulfasalazine, as it can worsen certain side effects. Taking the medication with a full glass of milk is not necessary for Sulfasalazine administration. Expecting stools to be black and tarry is not an expected side effect of Sulfasalazine.
4. Which of the following conditions is not treated with Dexamethasone?
- A. Inflammation
- B. Asthma
- C. Addison’s disease
- D. Wilson’s disease
Correct answer: D
Rationale: Dexamethasone is not used to treat Wilson’s disease. It is a corticosteroid primarily used for conditions like inflammation, asthma, and Addison’s disease. Wilson’s disease is a genetic disorder involving copper accumulation and is treated with medications like chelating agents or zinc salts, not Dexamethasone.
5. A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by IV bolus over 5 minutes.
- C. Dilute the medication in a 5% dextrose and water solution.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access